bw 12c79 has been researched along with Anemia, Sickle Cell in 7 studies
*Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kenny, MW; Stuart, J | 1 |
| Culliford, SJ; Ellory, JC; Mojiminiyi, FB; Stone, PC; Stuart, J | 1 |
| Beuzard, Y; Chrétien, N; De Paepe, ME; Hoang, T; Jacmain, J; Saadane, N; Sorette, M; Trudel, M | 1 |
| Nash, GB; Stone, PC; Stuart, J | 1 |
| Littlewood, T; van Rhee, F; Ware, I | 1 |
| Johnson, CS; Keidan, AJ; Marwah, SS; Sowter, MC; Stuart, J | 1 |
| Franklin, IM; Huehns, ER; Joy, M; Keidan, AJ; Stuart, J; White, RD | 1 |
1 trial(s) available for bw 12c79 and Anemia, Sickle Cell
| Article | Year |
|---|---|
Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease.
Topics: Adult; Aldehydes; Anemia, Sickle Cell; Aspartate Aminotransferases; Benzaldehydes; Bilirubin; Binding, Competitive; Clinical Trials as Topic; Dose-Response Relationship, Drug; Erythrocyte Count; Erythrocyte Deformability; Hemoglobin, Sickle; Hemolysis; Humans; Infusions, Parenteral; Leukocyte Count; Male; Oxygen; Oxygen Consumption; Oxyhemoglobins; Thalassemia; Time Factors | 1986 |
6 other study(ies) available for bw 12c79 and Anemia, Sickle Cell
| Article | Year |
|---|---|
Preservation of deformability (filterability) of sickle cells by BW12C during progressive deoxygenation.
Topics: Aldehydes; Anemia, Sickle Cell; Benzaldehydes; Dose-Response Relationship, Drug; Erythrocytes; Filtration; Hemoglobin SC Disease; Humans; Oxidation-Reduction; Oxygen; Partial Pressure | 1983 |
Additive in vitro effects of anti-sickling drugs.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Calcium; Cells, Cultured; Clotrimazole; Drug Synergism; Erythrocyte Deformability; Erythrocyte Indices; Erythrocytes; Hemorheology; Humans; Nitrendipine; Oxidation-Reduction; Potassium; Potassium Channels; Verapamil | 1994 |
Sickle cell disease of transgenic SAD mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Benzaldehydes; Disease Models, Animal; Erythrocytes, Abnormal; Erythropoiesis; Hypoxia; Longevity; Lung; Mice; Mice, Transgenic; Microcirculation; Spleen | 1994 |
Substituted benzaldehydes (12C79 and 589C80) that stabilize oxyhaemoglobin also protect sickle cells against calcium-mediated dehydration.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Benzoates; Calcium; Dehydration; Erythrocytes, Abnormal; Humans; Oxyhemoglobins; Potassium | 1992 |
Abnormal haemoglobin electrophoresis caused by BW 12C.
Topics: Adenocarcinoma; Anemia, Sickle Cell; Antineoplastic Agents; Benzaldehydes; Blood Protein Electrophoresis; False Negative Reactions; Hemoglobins; Humans; Male; Middle Aged | 1992 |
Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease.
Topics: Anemia, Sickle Cell; Benzaldehydes; Benzoates; Erythrocyte Deformability; Hemoglobin, Sickle; Humans; Oxygen | 1989 |